Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a synthetic analog of vasotocin (arginine vasotocin, AVT), which is a neurohypophyseal peptide hormone found in non-mammalian vertebrates. The nomenclature indicates specific modifications to the vasotocin structure: a D-amino acid substitution with a 5-carbon methylene bridge, a methylated tyrosine at position 2, and ornithine substituted for arginine at position 8. Vasotocin is homologous to mammalian vasopressin and oxytocin, and acts as an endocrine regulator for water balance, osmotic homeostasis, and is involved in social and sexual behavior. This synthetic analog was likely designed to modify the pharmacological properties of native vasotocin, potentially altering receptor selectivity, duration of action, or metabolic stability.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [D-(CH2)5,Tyr(Me)2,Orn8]vasotocin.